Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
81 Results Found
Senate Aging Committee holds hearing on transparency, health care costs
The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs.
HHS announces reduced beneficiary coinsurance for 64 Medicare Part B prescription drugs
The Department of Health and Human Services June 26 announced beneficiary coinsurance reductions for 64 prescription drugs available through Medicare Part B.
AHA Letter to Reps. Fischbach and Pence Expressing Support of Congressional Review Act (CRA) Resolutions
AHA writes in support of H.J.Res. 139, a joint resolution for congressional disapproval of a rule relating to "Medicare and Medicaid Programs; Minimum Staffing Standards for Long-Term Care Facilities and Medicaid Institutional Payment Transparency Reporting."
Mark Cuban Lays Out More Details about How He’s Disrupting Drug Pricing
Learn how Mark Cuban is disrupting drug pricing and making waves in the pharmaceutical industry. Find out more about his Cost Plus Drugs company and its collaborations with payers and pharmacists.
Blog, infographic highlight how increasing drug prices and shortages are jeopardizing access to care
The AHA May 22 released a new infographic and blog highlighting how increasing drug prices and shortages are jeopardizing patient access to hospital care and exacerbating challenges hospitals are experiencing.
Drug Prices and Shortages Increase Hospitals’ Costs and Jeopardize Patient Access to Care Infographic
Drug companies continue to introduce new drugs at record prices. The median annual list price for new drugs in 2023 was $300,000, an increase of 35% over the previous year.
Drug Prices and Shortages Jeopardize Patient Access to Quality Hospital Care
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient o
3 Ways GLP-1 Drugs Could Impact Your Hospital’s Future
Glucagon-like peptide-1 agonist drugs have been surging in popularity, and manufacturers are scurrying to keep up with demand. Overall, the GLP-1 market is expected to experience annual growth exceeding 20% and will hit $133 billion worldwide by 2030, according to a MarketWatch report from February.
CMS opens comment period for Medicare Drug Price Negotiation Program
The Centers for Medicare & Medicaid Services May 3 announced the opening of the comment period for the Inflation Reduction Act’s Medicare Drug Price Negotiation Program, which will negotiate prices with drug makers for certain high-cost, sole-source drugs and apply them beginning in 2026. Comments are due July 2.
HRSA Finalizes 340B Administrative Dispute Resolution Process
The Department of Health and Human Services (HHS) and the Health Resources and Services Administration (HRSA) April 19 published the 340B Administrative Dispute Resolution (ADR) final rule establishing a process that was required under the Affordable Care Act.